Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.
2.

Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.

Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM; ACRIN Trial Team and I-SPY 2 TRIAL Investigators.

J Magn Reson Imaging. 2018 Oct 22. doi: 10.1002/jmri.26539. [Epub ahead of print]

PMID:
30350329
3.

Precision risk-based screening might maximize benefit and minimize harm.

Esserman LJ, LaCroix AZ.

Nat Rev Clin Oncol. 2018 Nov;15(11):661-662. doi: 10.1038/s41571-018-0093-0. No abstract available.

PMID:
30218030
4.

Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer.

Magbanua MJM, Rugo HS, Hauranieh L, Roy R, Scott JH, Lee JC, Hsiao F, Sosa EV, Van't Veer L, Esserman LJ, Park JW.

NPJ Breast Cancer. 2018 Sep 5;4:31. doi: 10.1038/s41523-018-0083-5. eCollection 2018.

5.

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.

Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators.

Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4.

PMID:
30179110
6.

Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.

Tang V, Zhao S, Boscardin J, Sudore R, Covinsky K, Walter LC, Esserman L, Mukhtar R, Finlayson E.

JAMA Surg. 2018 Aug 29. doi: 10.1001/jamasurg.2018.2736. [Epub ahead of print]

PMID:
30167636
7.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators.

NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. Review.

8.

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.

Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y.

NPJ Breast Cancer. 2018 Aug 16;4:24. doi: 10.1038/s41523-018-0078-2. eCollection 2018.

9.

Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers.

Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR, Beswick A, Greenwood R, Ingram JC, Saunders C, Vaidya JS, Esserman L, Jatoi I, Brunt AM.

BJS Open. 2018 May 22;2(4):162-174. doi: 10.1002/bjs5.53. eCollection 2018 Aug. Review.

10.

Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.

Mukhtar RA, Wong J, Piper M, Zhu Z, Fahrner-Scott K, Mamounas M, Sbitany H, Alvarado M, Foster R, Ewing C, Esserman L.

Ann Surg Oncol. 2018 Oct;25(11):3165-3170. doi: 10.1245/s10434-018-6682-4. Epub 2018 Jul 27.

PMID:
30054826
11.

The DigniCap Scalp Cooling System and its use in the treatment of chemotherapy-induced alopecia.

Mustoe MM, Lee CM, Melisko ME, Esserman LJ, Rugo HS.

Future Oncol. 2018 Oct;14(24):2461-2469. doi: 10.2217/fon-2018-0178. Epub 2018 Jul 12.

PMID:
30001151
12.

MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.

Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

AJR Am J Roentgenol. 2018 Jun;210(6):1376-1385. doi: 10.2214/AJR.17.18323. Epub 2018 Apr 30.

PMID:
29708782
13.

Improved analgesia and reduced post-operative nausea and vomiting after implementation of an enhanced recovery after surgery (ERAS) pathway for total mastectomy.

Chiu C, Aleshi P, Esserman LJ, Inglis-Arkell C, Yap E, Whitlock EL, Harbell MW.

BMC Anesthesiol. 2018 Apr 16;18(1):41. doi: 10.1186/s12871-018-0505-9.

14.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
15.

Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels.

Kwong A, Ho JCW, Shin VY, Kurian AW, Tai E, Esserman LJ, Weitzel JN, Lin PH, Field M, Domchek SM, Lo J, Ngan HYS, Ma ESK, Chan TL, Ford JM.

Oncotarget. 2017 Dec 20;9(8):7832-7843. doi: 10.18632/oncotarget.23471. eCollection 2018 Jan 30.

16.

Initial Clinical Experience With an Inducible Magnetic Seed System for Preoperative Breast Lesion Localization.

Price ER, Khoury AL, Esserman LJ, Joe BN, Alvarado MD.

AJR Am J Roentgenol. 2018 Apr;210(4):913-917. doi: 10.2214/AJR.17.18345. Epub 2018 Feb 15.

PMID:
29446680
17.

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group.

J Natl Cancer Inst. 2018 Jul 1;110(7):726-733. doi: 10.1093/jnci/djx270.

18.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

19.

Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.

DeMichele A, Yee D, Esserman L.

N Engl J Med. 2017 Dec 7;377(23):2287-2289. doi: 10.1056/NEJMcibr1711545. No abstract available.

PMID:
29211674
20.

The value of embedding: integrated palliative care for patients with metastatic breast cancer.

Rabow M, Small R, Jow A, Majure M, Chien A, Melisko M, Belkora J, Esserman LJ, Rugo H.

Breast Cancer Res Treat. 2018 Feb;167(3):703-708. doi: 10.1007/s10549-017-4556-2. Epub 2017 Oct 30.

PMID:
29086230
21.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

22.

The WISDOM Study: breaking the deadlock in the breast cancer screening debate.

Esserman LJ; WISDOM Study and Athena Investigators.

NPJ Breast Cancer. 2017 Sep 13;3:34. doi: 10.1038/s41523-017-0035-5. eCollection 2017. Review.

23.

Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.

Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME.

Breast Cancer Res Treat. 2018 Jan;167(1):117-122. doi: 10.1007/s10549-017-4506-z. Epub 2017 Sep 18.

PMID:
28921303
24.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.

Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L.

Breast Cancer Res. 2017 Sep 11;19(1):107. doi: 10.1186/s13058-017-0896-4.

25.

Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.

Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A.

Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.

PMID:
28830795
26.

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.

van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS.

Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4.

27.

Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction.

Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B.

Ann Plast Surg. 2018 Jan;80(1):10-13. doi: 10.1097/SAP.0000000000001186.

PMID:
28671888
28.

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.

Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS.

JAMA Oncol. 2017 Nov 1;3(11):1503-1510. doi: 10.1001/jamaoncol.2017.1261.

29.

Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):161. doi: 10.1007/s10549-017-4350-1. No abstract available.

PMID:
28660429
30.
31.

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY.

Breast Cancer Res Treat. 2017 Aug;165(1):181-191. doi: 10.1007/s10549-017-4303-8. Epub 2017 Jun 2.

32.

Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.

Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP.

Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13. Erratum in: Breast Cancer Res Treat. 2017 Aug;165(1):161.

PMID:
28503722
33.

Precision surgery and avoiding over-treatment.

Hosseini A, Khoury AL, Esserman LJ.

Eur J Surg Oncol. 2017 May;43(5):938-943. doi: 10.1016/j.ejso.2017.02.003. Epub 2017 Feb 11. Review.

PMID:
28238520
34.

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.

Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB Jr, Ver Hoeve ES, Esserman L, Cigler T.

JAMA. 2017 Feb 14;317(6):606-614. doi: 10.1001/jama.2016.21038.

35.

Preoperative MRI Evaluation of Axillary Lymph Nodes in Invasive Ductal Carcinoma: Comparison of Luminal A Versus Luminal B Subtypes in a Paradigm Using Ki-67 and Receptor Status.

Plaza MJ, Handa P, Esserman LE.

AJR Am J Roentgenol. 2017 Apr;208(4):910-915. doi: 10.2214/AJR.15.15788. Epub 2017 Jan 31.

PMID:
28140614
36.

Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.

Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA; Athena Breast Health Network Investigators.

J Natl Cancer Inst. 2017 Jan 27;109(5). doi: 10.1093/jnci/djw290. Print 2017 Jan. Review.

PMID:
28130475
37.

Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM.

Clin Breast Cancer. 2017 Jun;17(3):e155-e159. doi: 10.1016/j.clbc.2016.12.008. Epub 2016 Dec 29. No abstract available.

PMID:
28110902
38.

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.

Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

Tomography. 2016 Dec;2(4):378-387. doi: 10.18383/j.tom.2016.00247.

39.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

40.

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.

Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM; ACRIN Trial team ISPY-1 Investigators.

J Magn Reson Imaging. 2017 Jul;46(1):290-302. doi: 10.1002/jmri.25560. Epub 2016 Dec 16.

41.

The I-SPY approach to drug development.

Esserman L.

Clin Adv Hematol Oncol. 2016 Oct;14(10):782-784. No abstract available.

PMID:
27930629
42.

Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.

JAMA Oncol. 2017 Mar 1;3(3):313-319. doi: 10.1001/jamaoncol.2016.3904.

PMID:
27832260
43.

Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.

Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C.

Breast Cancer Res Treat. 2017 Jan;161(1):41-50. doi: 10.1007/s10549-016-4041-3. Epub 2016 Nov 4.

PMID:
27815749
44.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Berry D, Esserman L.

N Engl J Med. 2016 Oct 20;375(16):1592-3. doi: 10.1056/NEJMc1609993. No abstract available.

PMID:
27797314
45.

Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.

Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L.

Breast Cancer Res Treat. 2017 Jan;161(1):17-28. doi: 10.1007/s10549-016-4036-0. Epub 2016 Oct 26.

46.

PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.

Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ.

Clin Pharmacol Ther. 2016 Dec;100(6):713-729. doi: 10.1002/cpt.514. Epub 2016 Oct 19.

47.
48.

Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction?

Wang F, Chin R, Piper M, Esserman L, Sbitany H.

Plast Reconstr Surg. 2016 Dec;138(6):1141-1149. Review.

PMID:
27537226
49.

The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.

Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ.

Am J Transplant. 2017 Jan;17(1):292-295. doi: 10.1111/ajt.14003. Epub 2016 Sep 7.

50.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

Supplemental Content

Loading ...
Support Center